Chronická myeloidní leukemie - potřebujeme ještě nové inhibitory tyrosinkináz?
| Title in English | Chronic myeloid leukemia - do we still need new tyrosine kinase inhibitors? |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Onkologická revue |
| MU Faculty or unit | |
| Citation | |
| Web | https://onkologickarevue.cz/cs/chronicka-myeloidni-leukemie-potrebujeme-jeste-nove-inhibitory-tyrosinkinaz |
| Keywords | chronic myeloid leukemia; tyrosine kinase inhibitors; asciminib |
| Description | Asciminib is the newest tyrosine kinase inhibitor used for chronic myeloid leukemia patients' therapy. Asciminib binds a myristoyl pocket of the BCR::ABL1, locking BCR::ABL1 into an inactive conformation. A different mechanism of action may be an advantage in the case of TKIs' acting via the ATP-binding domain failure, and a favorable side effect profile is expected. The following case report describes a chronic myeloid leukemia patient benefitting from the use of asciminib not only by means of achieving a deep molecular response but also of a good quality of life. |
| Related projects: |